BRCA screening has its limits in assessing dangers for women with a family history of disease, experts say
FRIDAY, Sept. 6 (HealthDay News) -- U.S. Food and Drug Administration approval for Abraxane (paclitaxel) has been expanded to include advanced pancreatic cancer, the agency said Friday in a news release.
The agency previously approved the chemotherapy drug to treat cancers of the lung and breast.
Some 45,220 people are expected to be diagnosed with pancreatic cancer this year, and an estimated 38,460 will die from it, the FDA said.
Pancreatic cancer is the fourth-leading cause of cancer death. Surgery is the only way to permanently remove pancreatic cancer, but it's usually too late for surgery by the time most cases are identified, the agency said.
Abraxane's safety and effectiveness in treating pancreatic cancer were evaluated in clinical trials involving 861 people. Those treated with Abraxane and another chemotherapy drug, gemcitabine, lived an average of 1.8 months longer than those treated with gemcitabine alone.
Common side effects of the drug combination included a drop in white blood cells and blood platelets, fatigue, nerve damage in the extremities, vomiting, diarrhea and fever.
Abraxane is marketed by Celgene, based in Summit, N.J.
Medline Plus has more about pancreatic cancer.
Copyright © 2013 HealthDay. All rights reserved.
Mon Sep 23, 2013 11:04 PM
Not particularly exciting news. A new expensive and toxic drug that gives patients on average of 1.8 months extra life.
Sat Oct 19, 2013 01:07 AM
Abraxane is a deadly poision and any one giving this to a patient should be charged with murder. It's another were right on the verge product. Total b.s.
Mon Dec 09, 2013 11:03 PM
I just finished a 2-month course of Abraxane and Gemzar. Major side effects were joint and muscle pain, and fatigue. The other side effect was that my CA19-9 dropped from 497 to 27. I've been on haitus for five weeks now, and just had a blood test that showed a CA19-9 of 64.3.
It may be a deadly poison for you, but it seems to be working pretty well for me!
We care about your feedback. Let us know how we can improve your CancerCompass experience.